Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Uterine fibroids Stories

2012-03-13 10:00:00

BETHESDA, Md., March 13, 2012 /PRNewswire/ -- American Capital, Ltd. (Nasdaq: ACAS) announced today that it has invested $11.7 million, $20 million together with its affiliates, in the debt and equity of portfolio company Halt Medical, Inc., a medical device company focused on women's health. "American Capital is pleased to be supporting our portfolio company Halt Medical as it continues to grow its medical device business focused on treating uterine fibroids," said Gordon O'Brien,...

2012-03-12 08:05:00

PARSIPPANY, N.J., March 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced it has initiated its Phase 3 trial to evaluate the efficacy and safety of Esmya® (ulipristal acetate) in women with anemia associated with uterine leiomyomas, a medical condition often referred to as uterine fibroids (myomas). Leiomyomata are benign solid tumors that often lead to excessive menstrual bleeding, anemia and pain, which ultimately may require surgical...

2012-03-02 01:38:40

NIH-funded study suggests possible treatment for common condition Treatment with vitamin D reduced the size of uterine fibroids in laboratory rats predisposed to developing the benign tumors, reported researchers funded by the National Institutes of Health. Uterine fibroids are the most common noncancerous tumors in women of childbearing age. Fibroids grow within and around the wall of the uterus. Thirty percent of women 25 to 44 years of age report fibroid-related symptoms, such as...

2012-02-11 05:00:00

LIVERMORE, Calif., Feb. 11, 2012 /PRNewswire/ -- Halt Medical, Inc. announced today that it has closed on the first $20 million of a planned $50 million debt and equity financing. "Leading the financing with the first $20 million is our long term investment partner American Capital Strategies (ACAS). American Capital's financial resources, global perspective and life science expertise has made them the perfect financing partner for Halt Medical. Following the lead of American Capital,...

2011-11-27 03:00:00

TIRAT CARMEL, Israel, November 27, 2011 /PRNewswire/ -- InSightec Ltd announced that NICE, the National Institute for Health and Clinical Excellence of the NHS in the UK, announced new favorable guidelines for the treatment of uterine fibroids using MR guided Focused Ultrasound. The new guidelines state that the current evidence on the efficacy of magnetic resonance image (MRI)-guided transcutaneous focused ultrasound treatment for uterine fibroids and evidence on safety are...

2011-11-14 23:05:21

In a finding that confirms what many obstetricians and gynecologists suspected, Duke University researchers report that younger women who undergo hysterectomies face a nearly two-fold increased risk for developing menopause early. The study, published in the December issue of the journal Obstetrics & Gynecology, is the largest analysis to track over time the actual hormonal impact of woman who had hysterectomies and compare them to women whose uteruses remained intact. "Hysterectomy...

2011-11-07 08:35:00

BEDFORD, Mass., Nov. 7, 2011 /PRNewswire/ -- Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, will showcase a comprehensive suite of gynecologic surgical products at AAGL 40th Annual Global Congress of Minimally Invasive Gynecology, November 6-10, 2011, at the Westin-Diplomat Hotel in Hollywood, Florida....

2011-10-31 15:05:00

SAN DIEGO, Oct. 31, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended September 30, 2011. For the third quarter of 2011, the Company reported net income of $31.4 million, or $0.56 per fully diluted share outstanding, compared to net income of $3.3 million, or $0.06 per fully diluted share outstanding, for the same period in 2010. For the nine months ended September 30, 2011, the Company reported a net income of...

2011-09-28 09:14:57

Researchers have found the first, firm evidence that fibroids are associated with recurrent miscarriages. They have also discovered that if they removed the fibroids that distorted the inside of the womb, the risk of miscarriage in the second trimester of pregnancy was reduced dramatically — to zero. The study, which is published online in Europe's leading reproductive medicine journal Human Reproduction today (Wednesday), is the culmination of 20 years of investigation into...

2011-09-27 07:30:00

SAN DIEGO, Sept. 27, 2011 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that an elagolix podium presentation has been accepted for the scientific program at the 2011 Annual Meeting of the American Society for Reproductive Medicine, to be held October 15-19, 2011 in Orlando, Florida. This annual meeting draws over 4,000 experts from around the world to address current topics related to human reproduction. "We are very pleased to participate in the annual...